OncoSec Medical (NSDQ:ONCS) announced today that it received CE mark approval for its next-generation device to enable better uptake of anti-cancer therapies. GenPulse, part of OncoSec’s electroporation device platform for treating solid tumors, is designed to apply short electric impulses to a tumor, according to a news release. The electric impulses cause pores to open […]
OncoSec Medical
OncoSec, Inovio testing COVID-19 vaccines
OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. Get the full […]
OncoSec $30m fundraise threatened by spat
OncoSec Medical (NSDQ:ONCS) is embroiled in a lawsuit and proxy war over a $30 million money-raise as it seeks to continue development of its cancer treatment technology. The company — headquartered in San Diego and Pennington, N.J. — sent a letter to shareholders today in which it countered what it described as false and misleading statements […]
OncoSec shares fall on preliminary data from skin cancer trial
Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. Get the full story at our sister […]
OncoSec inks research deal to analyze clinical trial participants
OncoSec Medical (NSDQ:ONCS) said today that it inked a research deal with Dr. Roger Lo and his research team at the University of California Los Angeles to study participants from the biotech company’s Pisces/Keynote-695 Phase IIb clinical trial. Dr. Lo and his team are slated to perform genetic, transcriptomic and methylomic analyses of patients from OncoSec’s […]
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer. The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed at […]
OncoSec looks to boost effects of immunotherapy with intratumoral delivery
Thousands of cancer patients have been treated with immune checkpoint inhibitors since the first of its kind was approved in 2011. The product is designed to block the production of proteins that prevent the body’s immune system from acting in the presence of cancer. Although checkpoint inhibitors hold immense promise for some patients, many fail to […]
OncoSec Medical prices $20m public offering
OncoSec Medical (NSDQ:ONCS) today priced an underwritten public offering of 13,333,334 shares of its common stock at $1.50 apiece. The San Diego, Calif.-based company expects the offering to bring in $20 million to help fund its Phase II melanoma trial, as well as other clinical and R&D activities. Get the full story at our sister site, […]
OncoSec Medical lands $9.3m in warrant exercise deal
OncoSec Medical (NSDQ:ONCS) said yesterday that it inked a warrant exercise agreement with unnamed holders of outstanding warrants to buy up to 5.5 million shares of the company’s common stock at an exercise price of $1.69 apiece. The San Diego, Calif.-based company raised $9.3 million in gross proceeds from the exercise of the warrants, which it plans to […]
OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017
OncoSec Medical (NSDQ:ONCS) announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]
OncoSec inks preclinical deal with Jounce Therapeutics
OncoSec Medical (NSDQ:ONCS) said today that it inked a preclinical deal with Jounce Therapeutics (NSDQ:JNCE) through the OncoSec Technology Access Program. According to the agreement, Jounce will have access to OncoSec’s gene delivery technology to assess the efficacy of intratumorally-delivered therapeutic candidates. The deal includes OncoSec’s Genesis research generator, which features customizable electroporation parameters for […]
